Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-naive Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase III study

Journal of Gastroenterology

Volumn 51, Issue 4, 2016, Pages 390-403

  Hayashi, Norio ^a   Nakamuta, Makoto ^b   Takehara, Tetsuo ^c   Kumada, Hiromitsu ^d   Takase, Akiko ^e   Howe, Anita Yee Mei ^f   Ludmerer, Steven W ^f   Mobashery, Niloufar ^f  

^a KANSAI ROSAI HOSPITAL   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d TORANOMON HOSPITAL   (Japan)

^e Merck Sharp Dohm Res Labs Japan   (Japan)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Hepatitis C virus; Japan; Peginterferon; Ribavirin; Vaniprevir

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VANIPREVIR; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT; INDOLE DERIVATIVE; MACROGOL DERIVATIVE; MK-7009; RECOMBINANT PROTEIN;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLELE; ALOPECIA; ANEMIA; ANTIVIRAL RESISTANCE; ANXIETY; ARTHRALGIA; ARTICLE; ATRIAL FIBRILLATION; BILIRUBIN BLOOD LEVEL; CHONDROCALCINOSIS; CONTROLLED STUDY; DECREASED APPETITE; DEHYDRATION; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FATIGUE; FEMALE; FEVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENE MUTATION; GINGIVITIS; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS SUBTYPE 1A; HEPATITIS C VIRUS SUBTYPE 1B; HUMAN; INAPPROPRIATE VASOPRESSIN SECRETION; INTERSTITIAL LUNG DISEASE; JAPANESE (PEOPLE); LEUKOCYTE COUNT; LIVER CELL CARCINOMA; LIVER DISEASE; MAJOR CLINICAL STUDY; MALAISE; MALE; MEDICATION COMPLIANCE; MENIERE DISEASE; MIDDLE AGED; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; PRURITUS; RASH; RELAPSE; REPLICON; RETINOPATHY; RHINOPHARYNGITIS; SIDE EFFECT; STOMACH CANCER; SUDDEN DEAFNESS; SUSTAINED VIROLOGIC RESPONSE; THROMBOCYTE COUNT; TREATMENT RESPONSE; VIROLOGIC FAILURE; VOMITING; WILD TYPE; YOUNG ADULT; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DOUBLE BLIND PROCEDURE; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOLATION AND PURIFICATION; JAPAN; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; TREATMENT OUTCOME; VIROLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INDOLES; INTERFERON-ALPHA; JAPAN; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RECURRENCE; RIBAVIRIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84944585240     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-015-1120-x     Document Type: Article

References (19)

1. Chung H, Ueda T, Kudo M. Changing trends in hepatitis C infection over the past 50 years in Japan. Intervirology. 2010;53(1):39–43.
2. American Association for the Study of Liver Diseases, Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org (2014). Accessed 26 May 2015.
3. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol. 2014;60(2):392–420.
4. Lemoine M, Thursz M. Hepatitis C, a global issue: access to care and new therapeutic and preventive approaches in resource-constrained areas. Semin Liver Dis. 2014;34(1):89–97.
5. Hayashi N, Izumi N, Kumada H, et al. Simeprevir with peginterferon/ribavirin for treatment-naive hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. J Hepatol. 2014;61(2):219–27.
6. Kumada H, Toyota J, Okanoue T, et al. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol. 2012;56(1):78–84.
7. Hayashi N, Seto C, Kato M, et al. Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naive hepatitis C genotype 1-infected patients in Japan: the DRAGON study. J Gastroenterol. 2014;49(1):138–47.
8. Editors of the Drafting Committee for Hepatitis Management Guidelines: the Japan Society of Hepatology. Guidelines for the management of hepatitis C virus infection: first edition, May 2012, the Japan Society of Hepatology. Hepatol Res. 2013;43(1):1–34.
9. Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology. JSH guidelines for the management of hepatitis C virus infection: a 2014 update for genotype 1. Hepatol Res. 2014;44(Suppl S1):59–70.
10. Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014;59(6):2083–91.
11. McCauley JA, McIntyre CJ, Rudd MT, et al. Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor. J Med Chem. 2010;53(6):2443–63.
12. Liverton NJ, Carroll SS, Dimuzio J, et al. MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease. Antimicrob Agents Chemother. 2010;54(1):305–11.
13. Olsen DB, Davies ME, Handt L, et al. Sustained viral response in a hepatitis C virus-infected chimpanzee via a combination of direct-acting antiviral agents. Antimicrob Agents Chemother. 2011;55(2):937–9.
14. Manns MP, Gane E, Rodriguez-Torres M, et al. Vaniprevir with peginterferon alfa-2a and ribavirin in treatment-naive patients with chronic hepatitis C: a randomized phase 2 study. Hepatology. 2012;56(3):884–93.
15. Lawitz E, Rodriguez-Torres M, Stoehr A, et al. A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment. J Hepatol. 2013;59(1):11–7.
16. Rodriguez-Torres M, Stoehr A, Gane EJ, et al. Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of sustained viral response in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis. Clin Gastroenterol Hepatol. 2014;12(6):1029–37.
17. Hayashi N, Mobashery N, Izumi N. Vaniprevir plus peginterferon alfa-2a and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase II study. J Gastroenterol. 2015;50(2):238–48.
18. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4(2):213–26.
19. Ito K, Higami K, Masaki N, et al. The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B. J Clin Microbiol. 2011;49:1853–60.